Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Stoof, Susanne P ^a,b   Van Der Klis, Fiona R M ^a   Van Rooijen, Debbie M ^a   Knol, Mirjam J ^a   Sanders, Elisabeth A M ^b   Berbers, Guy A M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MENINGOCOCCUS VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; BACTERIUM ANTIBODY; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; VACCINE;

ADOLESCENT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INTERVENTION STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NETHERLANDS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; SEROTYPE; SERUM BACTERICIDAL ANTIBODY ASSAY; TIME TO TREATMENT; VACCINATION; ANTIBODY SPECIFICITY; IMMUNOLOGY; PROCEDURES; TIME;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; CHILD; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERVENTION STUDIES; MALE; MENINGOCOCCAL VACCINES; NETHERLANDS; TETANUS TOXOID; TIME FACTORS; VACCINATION; VACCINES, CONJUGATE;

EID: 84903515497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100651     Document Type: Article

References (40)

1. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, et al. (2013) Global epidemiology of invasive meningococcal disease. Popul Health Metr 11: 17.
2. Neppelenbroek SE, de Vries M, de Greeff SC, Timen A (2003) "Da's goed gedaan?" Report of the Dutch national vaccination campaign against meningococcal serogroup C disease in 2002. Utrecht: Municipal and Regional Health Service (GGD), The Netherlands.
3. van Lier EA, Oomen PJ, Mulder M, Conyn-van Spaendonck MAE, Drijfhout IH, et al. (2013) Vaccinatiegraad Rijksvaccinatieprogramma Nederland: Verslagjaar 2013 Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Nederland.
4. van 't Klooster T, de Melker H (2013) The National Immunisation Programme in the Netherlands: Developments in 2012. Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 201001002/2012.
5. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737-743. (Pubitemid 351364476)
6. Trotter CL, Gay NJ, Edmunds WJ (2005) Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162: 89-100. (Pubitemid 40885005)
7. Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10: 853-861.
8. Maiden MC, Stuart JM, Group UKMC (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
9. Trotter CL, Maiden MC (2009) Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 8: 851-861.
10. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367. (Pubitemid 38970013)
11. Borrow R, Andrews N, Findlow H, Waight P, Southern J, et al. (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17: 154-159.
12. de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, et al. (2010) Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One 5: e12144.
13. Khatami A, Snape MD, John T, Westcar S, Klinger C, et al. (2011) Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 30: 197-202.
14. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, et al. (2005) Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 24: 128-131. (Pubitemid 40250770)
15. Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, et al. (2008) The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 180: 2165-2173.
16. de Voer RM, van der Klis FR, Engels CW, Schepp RM, van de Kassteele J, et al. (2009) Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine 27: 6974-6982.
17. Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, et al. (2009) Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 127: 134-143.
18. Snape MD, Kelly DF, Salt P, Green S, Snowden C, et al. (2006) Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 43: 1387-1394. (Pubitemid 44845637)
19. Perrett KP, Winter AP, Kibwana E, Jin C, John TM, et al. (2010) Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 50: 1601-1610.
20. de Whalley PC, Snape MD, Plested E, Thompson B, Nuthall E, et al. (2013) Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 98: 686-691.
21. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, et al. (2008) Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336: 1487-1491. (Pubitemid 351977021)
22. de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, et al. (2011) Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatr Infect Dis J 30: e203-208.
23. European Centre for Disease Prevention and Control, Vaccine Scheduler (Acces date: January 6, 2014) available from: http://vaccine-schedule.ecdc. europa.eu/Pages/Scheduler.aspx.
24. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4: 156-167. (Pubitemid 27130227)
25. Andrews N, Borrow R, Miller E (2003) Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10: 780-786. (Pubitemid 37129487)
26. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23: 2222-2227. (Pubitemid 40341456)
27. de Voer RM, van der Klis FR, Engels CW, Rijkers GT, Sanders EA, et al. (2008) Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin Vaccine Immunol 15: 1188-1193.
28. Lal G, Balmer P, Joseph H, Dawson M, Borrow R (2004) Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 11: 272-279. (Pubitemid 38380806)
29. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA (2008) Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 335: 79-89.
30. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857-872.
31. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA (2009) Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 67: 301-308.
32. Khatami A, Peters A, Robinson H, Williams N, Thompson A, et al. (2011) Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clin Vaccine Immunol 18: 2038-2042.
33. Diez-Domingo J, Cantarino MV, Torrenti JM, Sansano MI, Rosich AJ, et al. (2010) A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 29: 148-152.
34. Findlow H, Borrow R, Andrews N, Waight P, Sheasby E, et al. (2012) Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. Pediatr Infect Dis J 31: 616-622.
35. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, et al. (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183: 160-163. (Pubitemid 32043057)
36. Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT (2013) Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model. Vaccine.
37. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, et al. (2003) Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 71: 5549-5555. (Pubitemid 37205605)
38. de Voer RM, van der Klis FR, Schepp RM, Rijkers GT, Sanders EA, et al. (2011) Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG. PLoS One 6: e23497.
39. Harris SL, Tsao H, Ashton L, Goldblatt D, Fernsten P (2007) Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol 14: 397-403. (Pubitemid 46732550)
40. Goldblatt D, Borrow R, Miller E (2002) Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 185: 397-400. (Pubitemid 34107255)